查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493516

基因组癌症面板和分析市场 - 全球行业规模、份额、趋势、机会和预测，按组织测试、癌症面板类型、癌症类型、应用、技术、最终用户、地区和竞争，2019 年-2029F

Genomic Cancer Panel & Profiling Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, By Tissue Testing, By Cancer Panel Type, By Cancer Type, By Application, By Technology, By End-User, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年，全球基因组癌症面板和分析市场估值为99.5 亿美元，预计在预测期内将稳定成长，到2029 年复合年增长率为9.43%。和转型，受到精准医学和基因组技术进步的推动。这个市场围绕着对癌症相关基因组改变的彻底分析，以指导个人化治疗策略。癌症基因组由与各种癌症类型相关的基因组组成，使临床医生能够找出患者肿瘤内的特定突变、拷贝数变异和其他遗传异常。这些资讯对于客製化治疗、预测治疗反应和理解癌症的遗传基础至关重要。下一代定序 (NGS) 技术非常有用，可实现高通量和详细的基因组分析。全球癌症发生率不断上升刺激了市场的扩张，凸显了精确诊断工具的必要性。

市场概况
预测期 2025-2029
2023 年市场规模 99.5亿美元
2029 年市场规模 170.2亿美元
2024-2029 年复合年增长率 9.43%
成长最快的细分市场 液体组织测试
最大的市场 北美洲

人工智慧和机器学习的结合增强了对复杂基因组资料的解释，促进更精确和更快的见解。生物技术公司和研究机构之间的合作推动创新和全面基因组分析解决方案的创建。这些合作关係促进了对癌症生物学的理解，并有助于确定新的治疗标靶。市场见证了向液体活检方法的转变，从而能够非侵入性地即时监测与癌症相关的基因改变。液体活检技术，例如循环肿瘤 DNA (ctDNA) 检查，有助于早期检测、治疗监测和微小残留疾病的评估。

此外，多组学整合的趋势将基因组资料与转录组学、蛋白质组学和其他组学资讯合併，提供了癌症生物学的整体视角。这种综合方法增强了生物标记和潜在治疗标靶的识别，促进对不同癌症类型背后的复杂分子机制的更全面了解。随着全球医疗保健领域越来越重视个人化和标靶治疗，基因组癌症面板和分析市场有望进一步成长，为精确的癌症诊断和治疗决策提供创新的解决方案。基因组技术及其应用的不断发展凸显了市场在推进个人化肿瘤学时代的动态性。

主要市场驱动因素

基因组技术的进步

癌症发生率上升

精准医疗计划

主要市场挑战

资料隐私和安全问题

对综合资料库的存取有限

主要市场趋势

越来越重视早期检测

细分市场洞察

组织测试见解

癌症类型见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球基因组癌症小组和分析市场前景

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 透过组织检测（固体组织检测、液体组织检测）
    • 依癌症面板类型（单基因面板、多基因面板）
    • 依癌症类型（肺癌、乳癌、结肠癌、摄护腺癌、其他）
    • 按应用（临床、研究）
    • 依技术（次世代定序 (NGS)、聚合酶连锁反应 (PCR)、萤光原位杂交 (FISH)、免疫组织化学 (IHC) 等）
    • 按最终使用者（医院、临床和诊断实验室、其他）
    • 按地区
    • 按公司划分 (2023)
  • 市场地图
    • 透过组织测试
    • 按癌症面板类型
    • 按癌症类型
    • 按申请
    • 依技术
    • 按最终用户
    • 按地区

第 6 章：亚太地区基因组癌症小组与分析市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 透过组织测试
    • 按癌症面板类型
    • 按癌症类型
    • 按申请
    • 依技术
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 7 章：欧洲基因组癌症小组和分析市场前景

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 透过组织测试
    • 按癌症面板类型
    • 按癌症类型
    • 按申请
    • 依技术
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章：北美基因组癌症小组和分析市场前景

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 透过组织测试
    • 按癌症面板类型
    • 按癌症类型
    • 按申请
    • 依技术
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 9 章：南美洲基因组癌症小组与分析市场前景

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 透过组织测试
    • 按癌症面板类型
    • 按癌症类型
    • 按申请
    • 依技术
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲基因组癌症小组及分析市场前景

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 透过组织测试
    • 按癌症面板类型
    • 按癌症类型
    • 按申请
    • 依技术
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 埃及

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：全球基因组癌症面板和分析市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • Agilent Technologies, Inc.
  • ARUP Laboratories Inc
  • Burning Rock Biotech Limited
  • US Caris MPI, Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Fulgent Genetics Inc.
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 23883

Global Genomic Cancer Panel & Profiling Market was valued at USD 9.95 billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 9.43% through 2029. The Global Genomic Cancer Panel & Profiling Market is undergoing remarkable growth and transformation, driven by advancements in precision medicine and genomic technologies. This market revolves around the thorough analysis of cancer-related genomic alterations to guide personalized treatment strategies. Genomic cancer panels, which consist of sets of genes associated with various cancer types, empower clinicians to pinpoint specific mutations, copy number variations, and other genetic abnormalities within a patient's tumor. This information is pivotal for tailoring therapies, predicting treatment responses, and comprehending the genetic underpinnings of cancer. Next-Generation Sequencing (NGS) technologies are instrumental, allowing for high-throughput and detailed genomic profiling. The market's expansion is spurred by the escalating global cancer incidence, underscoring the necessity for precise diagnostic tools.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 9.95 Billion
Market Size 2029USD 17.02 Billion
CAGR 2024-20299.43%
Fastest Growing SegmentLiquid tissue testing
Largest MarketNorth America

The incorporation of artificial intelligence and machine learning augments the interpretation of intricate genomic data, facilitating more precise and expedited insights. Collaborations between biotechnology firms and research institutions drive innovation and the creation of comprehensive genomic profiling solutions. These partnerships advance the comprehension of cancer biology and aid in identifying novel therapeutic targets. The market witnesses a shift towards liquid biopsy approaches, enabling non-invasive and real-time monitoring of cancer-related genetic alterations. Liquid biopsy techniques, such as the examination of circulating tumor DNA (ctDNA), contribute to early detection, treatment monitoring, and the evaluation of minimal residual disease.

Furthermore, the trend towards multi-omic integration, which merges genomic data with transcriptomics, proteomics, and other -omics information, offers a holistic perspective of cancer biology. This integrated approach enhances the identification of biomarkers and potential therapeutic targets, fostering a more thorough understanding of the complex molecular mechanisms underlying different cancer types. As the global healthcare landscape increasingly prioritizes personalized and targeted therapies, the Genomic Cancer Panel & Profiling Market is poised for further growth, delivering innovative solutions for precise cancer diagnostics and treatment decision-making. The continuous evolution of genomic technologies and their applications underscores the market's dynamic nature in advancing the era of personalized oncology.

Key Market Drivers

Advancements in Genomic Technologies

Advancements in genomic technologies have been instrumental in shaping the landscape of the Global Genomic Cancer Panel & Profiling Market, ushering in a new era of precision medicine. Next-Generation Sequencing (NGS) stands as a cornerstone in these advancements, revolutionizing the speed, efficiency, and depth of genomic analysis. The continuous evolution of NGS platforms has enabled researchers and clinicians to conduct comprehensive genomic profiling with unprecedented accuracy and scale. Improved sequencing speed and reduced costs have made genomic profiling more accessible, allowing for the analysis of a broader range of genes and facilitating a deeper understanding of cancer-related genetic alterations. Beyond NGS, other genomic technologies such as microarray-based platforms and digital PCR contribute valuable insights. Microarrays provide a high-throughput method for simultaneously examining the expression levels of multiple genes, aiding in the identification of biomarkers associated with specific cancers.

Digital PCR offers enhanced sensitivity in detecting rare genetic mutations, contributing to the precision of genomic profiling. The integration of artificial intelligence (AI) and machine learning (ML) has emerged as a transformative force in genomic data interpretation. Advanced algorithms analyze vast datasets, helping identify patterns, predict treatment responses, and discover novel genetic markers. This fusion of genomic technologies and AI not only accelerates the analysis process but also enhances the accuracy of identifying clinically relevant genomic alterations. The advent of single-cell genomics represents another breakthrough, allowing researchers to analyze individual cells within a heterogeneous tumor. This technology unveils the intra-tumor heterogeneity and provides a more nuanced understanding of the genetic diversity present in cancers. These collective advancements empower the Genomic Cancer Panel & Profiling Market to offer more comprehensive and precise insights into the genomic landscape of cancers. As these technologies continue to evolve, the market is poised to witness further refinement in diagnostic accuracy, therapeutic decision-making, and the realization of personalized treatment strategies for cancer patients globally.

Rising Cancer Incidence

The Global Genomic Cancer Panel & Profiling Market is significantly influenced by the alarming and escalating incidence of cancer worldwide. The pervasive rise in cancer cases serves as a driving force behind the increasing adoption of genomic technologies for comprehensive cancer profiling. Cancer remains a leading cause of morbidity and mortality globally, with new cases diagnosed each year reaching staggering numbers. This surge in cancer incidence intensifies the need for precise diagnostic tools that can unravel the intricate genetic underpinnings of various cancer types. Genomic cancer panels play a pivotal role in this scenario by offering a systematic approach to analyze the genetic alterations associated with specific cancers. As the diversity of cancer types expands, so does the demand for tailored genomic profiling solutions. The ability of genomic technologies, such as Next-Generation Sequencing (NGS), to analyze a multitude of genes simultaneously provides clinicians with a comprehensive view of the genomic landscape, aiding in the identification of key mutations, copy number variations, and other genetic abnormalities driving cancer progression.

The rising cancer incidence not only emphasizes the urgency for accurate and early diagnosis but also underscores the importance of personalized treatment strategies. Genomic profiling enables clinicians to identify specific genetic markers that guide the selection of targeted therapies, contributing to more effective and tailored interventions. The exploration of new and emerging biomarkers associated with different cancer types is fueled by the need to understand the molecular intricacies of each case, further amplifying the relevance and demand for genomic cancer panels. In conclusion, the relentless increase in cancer incidence acts as a catalyst for the Global Genomic Cancer Panel & Profiling Market, driving advancements in genomic technologies and fostering a paradigm shift towards precision medicine in the fight against cancer.

Precision Medicine Initiatives

Precision medicine initiatives are playing a pivotal role in shaping the trajectory of the Global Genomic Cancer Panel & Profiling Market, ushering in an era of personalized and targeted therapeutic approaches. These initiatives are driven by the recognition that each patient's cancer is unique, necessitating tailored treatment strategies based on the individual's genetic makeup. Genomic cancer panels stand at the forefront of this paradigm shift, enabling comprehensive analysis of the molecular alterations within a patient's tumor. The core principle of precision medicine is to match specific genomic aberrations with targeted therapies, optimizing treatment outcomes and minimizing adverse effects. As genomic technologies, particularly Next-Generation Sequencing (NGS), become more sophisticated and accessible, precision medicine initiatives gain momentum. Clinicians leverage genomic cancer panels to identify key genetic mutations, copy number variations, and other alterations that drive cancer progression.

This information becomes crucial for making informed decisions about the most effective therapies for a particular patient. These initiatives are often part of large-scale collaborative efforts involving healthcare institutions, research organizations, and biotechnology companies. The goal is to create extensive databases of genomic and clinical data, facilitating a deeper understanding of the genetic basis of cancer and refining treatment strategies. The integration of artificial intelligence and machine learning further enhances the interpretation of vast datasets, assisting clinicians in identifying relevant biomarkers and predicting treatment responses. Precision medicine initiatives contribute to the shift from a one-size-fits-all approach to cancer treatment to a more nuanced and individualized methodology. By aligning treatment plans with the specific genomic profile of each patient's cancer, these initiatives not only improve therapeutic efficacy but also pave the way for future advancements in oncology. The Global Genomic Cancer Panel & Profiling Market is intricately linked to the success and expansion of precision medicine initiatives, as they collectively drive innovation and bring about transformative changes in cancer care.

Key Market Challenges

Data Privacy and Security Concerns

Data privacy and security concerns constitute significant challenges within the Global Genomic Cancer Panel & Profiling Market. The extensive generation, storage, and sharing of genomic data raise crucial issues regarding patient confidentiality and protection. Genomic information is inherently sensitive, encompassing an individual's unique genetic makeup and potential predispositions to various health conditions, including cancer. Securing genomic data from unauthorized access, breaches, or misuse is paramount. The fear of data breaches and the potential misuse of this highly personal information contribute to concerns among patients, healthcare providers, and regulatory bodies.

The need to comply with stringent data protection regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States or the General Data Protection Regulation (GDPR) in Europe, adds an additional layer of complexity. The challenge lies in establishing robust and standardized security measures to safeguard genomic data throughout its lifecycle-from collection and storage to transmission and analysis. Implementing encryption, access controls, and secure data sharing protocols becomes essential. Striking a balance between facilitating data-driven healthcare advancements and ensuring stringent data privacy safeguards is imperative to foster trust among stakeholders and encourage the widespread adoption of genomic cancer panels. Addressing these concerns is critical to realizing the full potential of genomic data in advancing precision medicine and personalized cancer care.

Limited Access to Comprehensive Databases

Limited access to comprehensive databases poses a significant challenge to the Global Genomic Cancer Panel & Profiling Market. The success of precision medicine relies heavily on vast and diverse datasets that encompass genomic and clinical information from a wide range of populations and cancer types. However, the availability of such comprehensive databases is often constrained. Access to extensive datasets is crucial for identifying patterns, understanding the genetic basis of cancers, and discovering relevant biomarkers that can inform personalized treatment strategies. The challenge arises due to factors like restricted sharing of genomic data, varying data protection regulations, and the lack of standardized data-sharing frameworks. Building inclusive and representative databases becomes particularly challenging for rare cancers and underrepresented populations.

These limitations hinder the ability to draw meaningful conclusions from genomic profiling, potentially leaving gaps in our understanding of the genetic intricacies of certain cancers. Efforts to address this challenge involve fostering collaboration among researchers, healthcare institutions, and biotechnology companies to promote the sharing of data while adhering to ethical and legal considerations. Encouraging open data-sharing practices and establishing frameworks that ensure privacy and security can contribute to overcoming the hurdle of limited access to comprehensive databases, unlocking the full potential of genomic cancer panels in advancing precision oncology.

Key Market Trends

Rising Emphasis on Early Detection

The Global Genomic Cancer Panel & Profiling Market is witnessing a rising emphasis on early detection, marking a transformative shift in cancer care. Genomic cancer panels play a pivotal role in this paradigm by enabling the identification of genetic alterations associated with cancer at its incipient stages. Early detection through genomic profiling allows for the identification of specific biomarkers indicative of cancer predisposition or the presence of minimal residual disease. This emphasis on early detection aligns with the broader goal of intervening in cancer progression at its earliest, most treatable phases. Genomic cancer panels contribute to precision oncology by uncovering genetic signatures that may indicate a predisposition to certain cancers, enabling proactive screening and surveillance strategies.

The identification of actionable mutations early on facilitates the selection of targeted therapies, potentially improving treatment efficacy and patient outcomes. As healthcare systems increasingly recognize the value of early detection in reducing the burden of cancer, the adoption of genomic cancer panels for screening and early intervention is expected to rise, shaping a future where personalized, genomic-driven approaches contribute significantly to cancer prevention and early-stage management.

Segmental Insights

Tissue Testing Insights

Based on Tissue Testing, the Liquid tissue testing emerged as the fastest growing segment in the global genomic cancer panel and profiling market, especially for tissue testing. This trend signifies a shift towards utilizing liquid samples for testing, rather than traditional approaches, which is anticipated to gain prominence in cancer diagnosis and treatment. Liquid biopsy techniques, such as the analysis of circulating tumor DNA (ctDNA), offer non-invasive and real-time monitoring of cancer-related genetic changes. This approach is valuable for early detection, treatment monitoring, and assessing minimal residual disease. As liquid tissue testing continues to gain traction, it is expected to play a crucial role in enhancing our understanding of cancer biology and improving patient outcomes through personalized treatment strategies.

Cancer Type Insights

Based on cancer type, the lung cancer segment dominated the Global Genomic Cancer Panel & Profiling Market in 2023. This is ascribed due to its high prevalence and the critical role of genomic profiling in personalized treatment. As the leading cause of cancer-related deaths, lung cancer demands precise molecular analysis for targeted therapies. Genomic panels help identify specific mutations, guiding clinicians in selecting tailored treatments and improving patient outcomes. The increasing awareness of genomic testing benefits in lung cancer management, coupled with advancements in precision medicine, amplifies the prominence of lung cancer within the Genomic Cancer Panel & Profiling market, emphasizing the significance of genomic insights in optimizing therapeutic strategies for this prevalent and challenging malignancy.

Regional Insights

The dominance of the North America segment in the global Genomic Cancer Panel & Profiling Market is underpinned by several key factors. With a robust healthcare infrastructure and advanced research facilities, the region fosters the widespread adoption of genomic cancer profiling technologies. The presence of leading market players and increased investment in research and development initiatives further contribute to the region's leadership position.

A higher prevalence of cancer cases in North America, combined with a proactive approach towards early detection and personalized medicine, drives the demand for genomic cancer panels. The collaborative efforts among research institutions, pharmaceutical companies, and healthcare providers in the region play a pivotal role in enhancing the market's growth trajectory. These collective endeavors solidify North America's dominant position on the global stage of genomic cancer panel and profiling, shaping the landscape of cancer diagnostics and treatment strategies worldwide.

Key Market Players

Agilent Technologies, Inc

ARUP Laboratories Inc

Burning Rock Biotech Limited

U.S. Caris MPI, Inc.

Danaher Corporation

Exact Sciences Corporation

F. Hoffmann-La Roche Ltd

Fulgent Genetics Inc.

Illumina, Inc.

Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Genomic Cancer Panel & Profiling Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genomic Cancer Panel & Profiling Market, By Tissue Testing:

    Solid Tissue Testing Liquid Tissue Testing

Genomic Cancer Panel & Profiling Market, By Cancer Panel Type:

    Single-Gene Panel Multi-Gene Panel

Genomic Cancer Panel & Profiling Market, By Cancer Type:

    Lung Cancer Breast Cancer Colon Cancer Prostate Cancer Others

Genomic Cancer Panel & Profiling Market, By Application:

    Clinical Research

Genomic Cancer Panel & Profiling Market, By Technology:

    Next-Generation Sequencing (NGS) Polymerase Chain Reaction (PCR) Fluorescence In-Situ Hybridization (FISH) Immunohistochemistry (IHC) Others

Genomic Cancer Panel & Profiling Market, By End-User:

    Hospitals Clinical and Diagnostic Laboratories Others

Genomic Cancer Panel & Profiling Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Genomic Cancer Panel & Profiling Market.

Available Customizations:

Global Genomic Cancer Panel & Profiling Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genomic Cancer Panel & Profiling Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Tissue Testing (Solid Tissue Testing, Liquid Tissue Testing)
    • 5.2.2. By Cancer Panel Type (Single-Gene Panel, Multi-Gene Panel)
    • 5.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer, Others)
    • 5.2.4. By Application (Clinical, Research)
    • 5.2.5. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 5.2.6. By End-User (Hospitals, Clinical and Diagnostic Laboratories, Others)
    • 5.2.7. By Region
    • 5.2.8. By Company (2023)
  • 5.3. Market Map
    • 5.3.1. By Tissue Testing
    • 5.3.2. By Cancer Panel Type
    • 5.3.3. By Cancer Type
    • 5.3.4. By Application
    • 5.3.5. By Technology
    • 5.3.6. By End-User
    • 5.3.7. By Region

6. Asia Pacific Genomic Cancer Panel & Profiling Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Tissue Testing
    • 6.2.2. By Cancer Panel Type
    • 6.2.3. By Cancer Type
    • 6.2.4. By Application
    • 6.2.5. By Technology
    • 6.2.6. By End-User
    • 6.2.7. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Genomic Cancer Panel & Profiling Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Tissue Testing
        • 6.3.1.2.2. By Cancer Panel Type
        • 6.3.1.2.3. By Cancer Type
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By Technology
        • 6.3.1.2.6. By End-User
    • 6.3.2. India Genomic Cancer Panel & Profiling Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Tissue Testing
        • 6.3.2.2.2. By Cancer Panel Type
        • 6.3.2.2.3. By Cancer Type
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By Technology
        • 6.3.2.2.6. By End-User
    • 6.3.3. Australia Genomic Cancer Panel & Profiling Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Tissue Testing
        • 6.3.3.2.2. By Cancer Panel Type
        • 6.3.3.2.3. By Cancer Type
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By Technology
        • 6.3.3.2.6. By End-User
    • 6.3.4. Japan Genomic Cancer Panel & Profiling Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Tissue Testing
        • 6.3.4.2.2. By Cancer Panel Type
        • 6.3.4.2.3. By Cancer Type
        • 6.3.4.2.4. By Application
        • 6.3.4.2.5. By Technology
        • 6.3.4.2.6. By End-User
    • 6.3.5. South Korea Genomic Cancer Panel & Profiling Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Tissue Testing
        • 6.3.5.2.2. By Cancer Panel Type
        • 6.3.5.2.3. By Cancer Type
        • 6.3.5.2.4. By Application
        • 6.3.5.2.5. By Technology
        • 6.3.5.2.6. By End-User

7. Europe Genomic Cancer Panel & Profiling Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Tissue Testing
    • 7.2.2. By Cancer Panel Type
    • 7.2.3. By Cancer Type
    • 7.2.4. By Application
    • 7.2.5. By Technology
    • 7.2.6. By End-User
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Genomic Cancer Panel & Profiling Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Tissue Testing
        • 7.3.1.2.2. By Cancer Panel Type
        • 7.3.1.2.3. By Cancer Type
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By Technology
        • 7.3.1.2.6. By End-User
    • 7.3.2. Germany Genomic Cancer Panel & Profiling Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Tissue Testing
        • 7.3.2.2.2. By Cancer Panel Type
        • 7.3.2.2.3. By Cancer Type
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By Technology
        • 7.3.2.2.6. By End-User
    • 7.3.3. Spain Genomic Cancer Panel & Profiling Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Tissue Testing
        • 7.3.3.2.2. By Cancer Panel Type
        • 7.3.3.2.3. By Cancer Type
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By Technology
        • 7.3.3.2.6. By End-User
    • 7.3.4. Italy Genomic Cancer Panel & Profiling Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Tissue Testing
        • 7.3.4.2.2. By Cancer Panel Type
        • 7.3.4.2.3. By Cancer Type
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By Technology
        • 7.3.4.2.6. By End-User
    • 7.3.5. United Kingdom Genomic Cancer Panel & Profiling Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Tissue Testing
        • 7.3.5.2.2. By Cancer Panel Type
        • 7.3.5.2.3. By Cancer Type
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By Technology
        • 7.3.5.2.6. By End-User

8. North America Genomic Cancer Panel & Profiling Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Tissue Testing
    • 8.2.2. By Cancer Panel Type
    • 8.2.3. By Cancer Type
    • 8.2.4. By Application
    • 8.2.5. By Technology
    • 8.2.6. By End-User
    • 8.2.6. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Genomic Cancer Panel & Profiling Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Tissue Testing
        • 8.3.1.2.2. By Cancer Panel Type
        • 8.3.1.2.3. By Cancer Type
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By Technology
        • 8.3.1.2.6. By End-User
    • 8.3.2. Mexico Genomic Cancer Panel & Profiling Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Tissue Testing
        • 8.3.2.2.2. By Cancer Panel Type
        • 8.3.2.2.3. By Cancer Type
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By Technology
        • 8.3.2.2.6. By End-User
    • 8.3.3. Canada Genomic Cancer Panel & Profiling Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Tissue Testing
        • 8.3.3.2.2. By Cancer Panel Type
        • 8.3.3.2.3. By Cancer Type
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By Technology
        • 8.3.3.2.6. By End-User

9. South America Genomic Cancer Panel & Profiling Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Tissue Testing
    • 9.2.2. By Cancer Panel Type
    • 9.2.3. By Cancer Type
    • 9.2.4. By Application
    • 9.2.5. By Technology
    • 9.2.6. By End-User
    • 9.2.7. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Genomic Cancer Panel & Profiling Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Tissue Testing
        • 9.3.1.2.2. By Cancer Panel Type
        • 9.3.1.2.3. By Cancer Type
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By Technology
        • 9.3.1.2.6. By End-User
    • 9.3.2. Argentina Genomic Cancer Panel & Profiling Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Tissue Testing
        • 9.3.2.2.2. By Cancer Panel Type
        • 9.3.2.2.3. By Cancer Type
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By Technology
        • 9.3.2.2.6. By End-User
    • 9.3.3. Colombia Genomic Cancer Panel & Profiling Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Tissue Testing
        • 9.3.3.2.2. By Cancer Panel Type
        • 9.3.3.2.3. By Cancer Type
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By Technology
        • 9.3.3.2.6. By End-User

10. Middle East and Africa Genomic Cancer Panel & Profiling Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Tissue Testing
    • 10.2.2. By Cancer Panel Type
    • 10.2.3. By Cancer Type
    • 10.2.4. By Application
    • 10.2.5. By Technology
    • 10.2.6. By End-User
    • 10.2.7. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Genomic Cancer Panel & Profiling Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Tissue Testing
        • 10.3.1.2.2. By Cancer Panel Type
        • 10.3.1.2.3. By Cancer Type
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By Technology
        • 10.3.1.2.6. By End-User
    • 10.3.2. Saudi Arabia Genomic Cancer Panel & Profiling Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Tissue Testing
        • 10.3.2.2.2. By Cancer Panel Type
        • 10.3.2.2.3. By Cancer Type
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By Technology
        • 10.3.2.2.6. By End-User
    • 10.3.3. UAE Genomic Cancer Panel & Profiling Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Tissue Testing
        • 10.3.3.2.2. By Cancer Panel Type
        • 10.3.3.2.3. By Cancer Type
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By Technology
        • 10.3.3.2.6. By End-User
    • 10.3.4. Egypt Genomic Cancer Panel & Profiling Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Tissue Testing
        • 10.3.4.2.2. By Cancer Panel Type
        • 10.3.4.2.3. By Cancer Type
        • 10.3.4.2.4. By Application
        • 10.3.4.2.5. By Technology
        • 10.3.4.2.6. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Genomic Cancer Panel & Profiling Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Agilent Technologies, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (In case of listed)
    • 15.1.5. Recent Developments
    • 15.1.6. SWOT Analysis
  • 15.2. ARUP Laboratories Inc
  • 15.3. Burning Rock Biotech Limited
  • 15.4. U.S. Caris MPI, Inc.
  • 15.5. Danaher Corporation
  • 15.6. Exact Sciences Corporation
  • 15.7. F. Hoffmann-La Roche Ltd
  • 15.8. Fulgent Genetics Inc.
  • 15.9. Illumina, Inc.
  • 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer